Inactive Instrument

Cannabis Science, Inc. Stock

Biotechnology & Medical Research

Latest news : Cannabis Science, Inc.

05/08/24	Strainsforpains, Inc. Signs an International Retail and Wholesale Cannabinoid Drug Commercialization Agreement with Cannabis Science, Inc	CI
21/04/23	GBX International Group Inc. agreed to Spin-Off Cannabis Science, Inc.	CI
10/08/21	Cannabis Science Inc. Successfully Launches its $CSI Cannabis Science Coin for its CSi-EDP Utility Project Valuation Tracking	CI
31/03/21	Thermic Sciences International signed a share exchange agreement to acquire Cannabis Science, Inc.	CI
27/09/19	NHS Industries, Ltd. and Cannabis Science, Inc. Agree to Terminate the Previously Announced Joint Venture Agreement	CI
28/08/19	Cannabis Science Partners With NHS Industries to Launch the CBIS CDN Economic Development Plan	CI
05/08/19	Cannabis Science Successfully Moves Operations to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations	CI
03/06/19	Cannabis Science, Inc. Appoints Sulma Mohammed to its Scientific Advisory Board	CI
20/05/19	Cannabis Science, Inc. and Dana-Farber Cancer Institute, Inc. Sign New Research Agreement to Investigate Proprietary Extract from Justicia Plant	CI
25/03/19	Cannabis Science Announces Formation of Cannabis Science Canada Inc	CI
25/03/19	Cannabis To Seek Acquisitions	CI
14/03/19	Cannabis Science, Inc. cancelled the acquisition of Novus Beverage Solutions Corp.	CI
25/02/19	Cannabis Science, Inc. Announces Intends to Expand the Scope of its Sponsored Research in Nigeria to Include Neurological Conditions, Including Post-Traumatic Stress Disorder	CI

More news

Press Releases: Cannabis Science, Inc.

26/11/19	Canopy Growth : BC Centre on Substance Use hosts inaugural Cannabis Science Symposium	AQ
06/09/19	Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements	GL
28/08/19	Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions	GL
15/08/19	Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally	GL
05/08/19	Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations	GL

More press releases

Managers and Directors: Cannabis Science, Inc.

Manager	Title	Age	Since
Raymond Dabney CEO	Chief Executive Officer	62	29/02/1996
Julius Garvey CTO	Chief Tech/Sci/R&D Officer	-	12/09/2018
Robert Kane DFI	Director of Finance/CFO	51	21/11/2013

Director	Title	Age	Since
Robert Kane BRD	Director/Board Member	51	25/11/2013
Raymond Dabney BRD	Director/Board Member	62	29/02/1996
Melvin Foote BRD	Director/Board Member	-	-

More insiders

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNABIS SCIENCE, INC.	-.--%	-53.77%	-	-	13.46M
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+33.41%	+79.20%	56.54B
ARGENX SE	-0.21%	-7.38%	+25.34%	+63.02%	53.6B
BIONTECH SE	-2.44%	+1.40%	-15.74%	-16.80%	22.91B
INSMED INCORPORATED	-2.85%	-7.78%	-8.09%	+346.36%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-0.92%	+20.31%	-12.15%	20.27B
GENMAB A/S	+0.79%	-1.06%	+29.29%	-33.32%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-5.88%	+16.30%	+540.37%	14.75B
EXELIXIS, INC.	-5.25%	-4.23%	+46.41%	+169.05%	13.33B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+163.08%	+280.43%	13.53B
Average	-0.11%	-3.79%	+34.48%	+157.35%	25.98B
Weighted average by Cap.	+0.23%	-2.96%	+28.67%	+119.98%

Cannabis Science, Inc. Stock

Stocks

Biotechnology & Medical Research

Latest news : Cannabis Science, Inc.

Press Releases: Cannabis Science, Inc.

Managers and Directors: Cannabis Science, Inc.

Bio Therapeutic Drugs

Company Profile